109881 Aventis

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 737-740

  Ojima, Iwao ^a   Geney, Raphaël ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; DEXAMETHASONE; DOCETAXEL; RPR 109881; RPR 109881A; TAXOID; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; CANCER; CANCER RESISTANCE; CLINICAL TRIAL; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; FATIGUE; GRANULOCYTOPENIA; HUMAN; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NONHUMAN; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0042666801     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. 220850 Rhône-Poulenc Rorer's product pipeline. Scrip 1996 2168 20
2. 288706 A phase I study of RPR-109881A in patients with advanced solid tumors. Hyodo I, Shimada Y, Tamura T, Kurata T, Saeki T, Takashima S, Fujiwara K, Wakasugi H, Sasaki Y Proc Am Soc Clin Oncol 1998 17 Abs 745
3. 288707 A phase I trial of RPR-109881A, a novel taxoid derivative, administered as a 24 hour continuous infusion. Slaughter M, Pazdur R, Hoff PM, Matei C, Brito R, Dumas P, Raber M, Yanowitz C, Vernillet L, Wertz D, Lebecq A, Besenval M Proc Am Soc Clin Oncol 1998 17 Abs 748
4. 291456 A phase I clinical and pharmacokinetic study of RPR 109881A, a new taxoid administered as a 1-hour infusion in patients with solid tumors. Sessa C, Cuvier C, Caldiera S, Vernillet L, Perard D, Riva A, Le Mouhaer S, Besenval M, Marty M Proc Am Soc Clin Oncol 1998 17 Abs 728
5. 291474 Phase I trial of the new taxoid RPR 109881A in a day 1 & 8 intravenous schedule every 3 weeks. An NCI Canada Clinical Trials Group Study. Eisenhauer E, Latreille J, Gelmon K, Fisher B, Daigneault L, Hostetler Yanowitz C, Lebecq A, Besenval M Proc Am Soc Clin Oncol 1998 17 Abs 746
6. 291478 A phase I and pharmacokinetics study of RPR 109881A given as a 6-hour iv infusion in patients with advanced solid tumors. Barthier S, Dieras V, Kalla S, Boaziz C, Beuzeboc P, Perard D, Le Mouhauer S, Guerin M, Semioend D, Besenval M, Pouillart P Proc Am Soc Clin Oncol 1998 17 Abs 747
7. 363554 Drug development pipeline: TXD-258, RPR-109881A. Aventis Pharma AG Company Communication 2002 April 19
8. 389608 Phase I and pharmacokinetic study of a new taxoid, PRP 109881A, given as a 1-hour intravenous in patients with advanced solid tumors. Kurata T, Shimada Y, Tamura T, Yamamoto N, Hyodo I, Saeki T, Takashima S, Fujiwara K, Wakasugi H, Kashimura M J Clin Oncol 2000 18 17 3164-3171
9. 409257 Aventis Pharma R and D day, London, May 15, 2001. Aventis Pharma AG Company Presentation 2001 May 15
10. 423465 Analyst Global Healthcare Conference: Aventis - Planning for sustained growth. Aventis Pharma AG Company Presentation 2001 September 25
11. 440299 FY 2001 analyst conference. Aventis Pharma AG Company Presentation 2002 February 13
12. 450735 Deutsche Bank Health Care Conference 2002. Aventis Pharma AG Company Presentation 2002 May 08
13. 454720 Therapeutic focus key to sustainable growth. Aventis SA Company Presentation 2002 June 12
14. 455004 Aventis R and D day 2002. Aventis Pharma AG Company Presentation 2002 June 18
15. 463854 Preclinical evaluation of new taxoids. Bissery MC Curr Pharm Design 2001 7 13 1251-1257
16. 464632 Bear Stearns 15th Annual Healthcare conference. Aventis SA Company Presentation 2002 September 17
17. 469611 Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentration. Jordan MA, Toso RJ, Wilson L Proc Natl Acad Sci USA 1993 90 20 9552-9556
18. 469615 Synthesis and structure-activity relationships of new second-generation taxoids. Ojima I, Wang T, Miller ML, Lin S, Borella CP, Geng X, Pera P, Bernacki RJ Bioorg Med Chem Lett 1999 9 24 3423-3428
19. 469620 Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. Gelmon KA, Latrielle J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E J Clin Oncol 2000 18 24 4098-4108
20. 469626 Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Sessa C, Cuvier C, Caldiera S, Bauer J, Van Den Bosch S, Monnerat C, Samiond D, Perard D, Lebecq A, Besenval M, Marty M Ann Oncol 2002 13 7 1140-1150 This article describes two phase I studies and some preclinical data, and summarizes all the phase I data obtained worldwide on 109881.
21. 469631 Taxol: Mechanisms of action and resistance. Horwitz SB, Chen D, Rao S, Ringel I, Shen HJ, Yang CP J Natl Cancer Inst 1993 15 55-61
22. 469633 19-Hydroxybaccatin III, 10-deacetylcephalomannine, and 10-deacetyltaxol: New antitumor taxanes from Taxus wallichiana. McLaughlin JL, Miller RW, Powell RG, Smith CR J Nat Prod 1981 44 3 312-319
23. 475604 The Investors' Guide to Therapeutics and Drug Pipelines. Plag S, Elton Farr S, Garcia Sagues U, Dodwell J, Hall F, Bedford T, Hilliker I Credit Suisse First Boston 2002 November
24. 477143 Pharmaceuticals. Lanone P, Muzard B, Cassarino L CDC IXIS Securities 2002 November 08
25. 486474 Presentation given by Igor Landau at the Aventis AGM 2003. Aventis SA Company Presentation 2003 April 17